Empower Your
Market Access
Team with AI
Streamline dossier creation, enhance payer communication, and drive better reimbursement decisions.
How A79 helps
A79 empowers Market Access teams to demonstrate the value of new therapies to payers, optimize patient access strategies, and achieve favorable reimbursement decisions, ultimately improving patient outcomes.
Patient Compliance and Satisfaction
Extract patient sentiments and concerns from every interaction
Understand barriers to compliance and optimize support
Proactively look for signs of non-complaince
Create visualizations and reports
Summary of Patient: SumeetB
Patient has expressed insurance concerns int he last 3 interactions. View raw data
High probability of being non.-compliant in. the next 3 months View similar past data
What is the ICER of NovoHeart compared to standard CHF treatments?
Based on our analysis, the incremental cost-effectiveness ratio (ICER) of NovoHeart compared to standard CHF treatments is estimated to be $45,000 per quality-adjusted life year (QALY) gained.
Health Economics and Outcomes Research (HEOR)
More comprehensive scientific surveillance of large and disparate sources
Automated monitoring of targeted literature and scientific sources and summarization
Trend identification and implication categorization; commercial, clinical, regulatory
Document and power point generation
Payer Dossier for CancerX
Executive summary: CancerX is a novel oral..
Product overview: CancerX is a selective inhi.
Clinical Evidence: A double blind phase 3 ...
Health Economic evidence: ICER of 45,000$ ..
Payer Value and Communications
Automated assembly of a cited dossier with supporting links
Suggested key findings from analysis of disparate information sources
Stratified payer profiles extracted from formulary decisions, reimbursement policies, disease and therapeutic area
Tailored communications based on sophisticated understanding of specific payer priorities
The features
Market Access
teams love
Conversational flow
Ask questions in natural language and receive instant, actionable answers. No coding or complex queries required.
We integrate with internal as well as external data sources to give you the most accurate information.
Request a demo
How many treatments are we evaluating?
What’s the main insight from this data?
Here are the main insights from the data provided:
1. Treatment Preferences in 3rd Line aCRC:
CANCERX + bevacizumab (TFD/PTI + Bev) is widely adopted as the standard of care in 3rd line aCRC treatment
This combination is preferred over monotherapy options
Fruquintinib is emerging as a potential 4th line option or for patients with poor performance status
2. Clinical Experience with CANCERX + Bev:
Generally well-tolerated with manageable side effects
Some practices use growth factor support (WBCS) to manage cytopenlas
Alternate dosing schedules (e.g., biweekly) are sometimes used to manage toxicity
3. Biomarker Testing:
cDNA testing is gaining interest but its clinical utility is still being evaluated
Some KOLs are cautious about over-reliance on cIDNA for treatment decisions
GPA (genomic profile analysis) testing practices vary among oncologists.
Your data includes 5 treatments. What would you like to explore next?
Export to Documents
Seamlessly integrate with your existing pharma systems and data sources for a unified and comprehensive view.
Charts
Transform your data into compelling visuals that reveal hidden trends and patterns. Easily customize and share your insights.
Dashboards with re-usable insights
Create interactive dashboards with customizable widgets to monitor key metrics and share insights across your organization.
Configure email alerts when there are significant changes to the answers in a dashboard.
Request a demo
Add to dashboard
Product Information: LYTGOBI (Futibatinib)
Based on the information provided in the table, here's a summary of the feedback and key insights about the product LYTGOBI (Futibatinib):
Efficacy
1. Good response rates and long duration of response:
Patients have shown responses lasting >2 years
Good efficacy reported, making it a go-to option for FGFR2 fusion or gene rearrangement
Exciting response rate and longer duration of response
PFS is longer than anticipated
2. Potential for use in specific patient populations:
• May be used immediately after first-line treatment in patients unable to tolerate Cisplatin
Safety and Adverse Events
1. Nail toxicities:
Case studies
See A79 in Action
Discover how A79 is driving measurable productivity improvements for our partners
The platform's AI-powered insights allow us to tailor our medical communications and deliver the right information to the right audience at the right time. This has significantly improved our engagement and strengthened our relationships with key opinion leaders.
Head of Medical Affairs
Leading Pharmaceutical Company
A79 has been a true partner in our AI journey, working hand-in-hand with us to build custom solutions that are not only powerful but also incredibly user-friendly. The platform has been enthusiastically embraced by our entire team.
Head of AI development
Leading Oncology Company
A79 has completely transformed my workflow. I can now access critical scientific information, prepare for HCP interactions, and generate insightful reports in a fraction of the time it used to take.
Senior MSL
Top 20 Pharma
Ready to Unlock Faster Insights?
Discover how A79 can transform your data analysis process.
Copyright A79® 2024